Skip to main content
. Author manuscript; available in PMC: 2021 Feb 2.
Published in final edited form as: J Vis Exp. 2020 Nov 3;(165):10.3791/61855. doi: 10.3791/61855

Figure 2. CRISPR/Cas9 mediated CD19 KO in B cells.

Figure 2.

Figure 2.

(A) Bar graph shows >70% cell recovery (left panel) and >80% viability (right panel) of cells post transfection were observed in both control and CD19 KO samples at 24-hour post electroporation. (B) Representative flow plots of CD19 gating of live cells shows 84.3% and 3.43% CD19 positive cells in the control sample and the CD19 KO sample, respectively. (C) Bar graph shows significant reduction of CD19 in the CRISPR/Cas9 mediated CD19 KO group (p≤0.0001).